Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|April 26, 2022
Adare Pharma Solutions: Integrated End-To-End CDMO Solutions…From Start To Finish
Author(s)Adare Pharma Solutions
Advertisement
Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise in complex oral formulations. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.
Adaptdose White Paper
Adaptdose™ allows drug developers to quickly create custom oral delivery systems and reduce time to market by eliminating the need to reformulate after Phase I in many cases.
Duragran White Paper
DuraGran® reduces the amount of excipients and/or process steps used to build beads or controlled release granules, and for higher concentration doses can spheronization and extrusion steps typically used.
DOWNLOAD
Adare Pharma Solutions Interactive Brochure
This interactive brochure allows you to click through and learn more about all of Adare Pharma Solutions' major service offerings, technology platforms, and global facilities.
DOWNLOAD
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5